SanofiLong
FDA approves Dupixent® (dupilumab) for moderate-to-severe atopic
REGN,SNY: Sanofi
2019-03-11 15:45:00
FDA approves Dupixent® (dupilumab) for moderate-to-severe atopic dermatitis in adolescents - PR Newswire
2019-03-11 15:45:00
FDA approves Dupixent® (dupilumab) for moderate-to-severe atopic dermatitis in adolescents - PR Newswire
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.